L Hyer - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

L Hyer

Showing results (101-110 of 106) with videos related to

Pageof 11

Sort By:

You have reached the last page of results.This site can display upto 106 results.

Molecular Cancer Therapeutics|May 23, 2024

PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast CancerAnran Chen, Beom-Jun Kim, Aparna Mitra, et al.

Cancer Cell|January 15, 2021

MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA DamagePeter Kalev, Marc L Hyer, Stefan Gross, et al.

Biorxiv : the Preprint Server for Biology|December 9, 2024

Reciprocal links between methionine metabolism, DNA repair and therapy resistance in glioblastomaNavyateja Korimerla, Baharan Meghdadi, Isra Haq, et al.

Nature Medicine|January 16, 2018

A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatmentMarc L Hyer, Michael A Milhollen, Jeff Ciavarri, et al.

Nature Communications|June 13, 2026

The PLK4 inhibitor RP-1664 demonstrates potent efficacy in neuroblastoma preclinical models through a dual mechanism of sensitivityIsabel Soria-Bretones, Matias Casás-Selves, Minu Samanta, et al.

Journal of Medicinal Chemistry|November 11, 2011

Discovery of a potent and orally bioavailable benzolactam-derived inhibitor of Polo-like kinase 1 (MLN0905)Matthew O Duffey, Tricia J Vos, Ruth Adams, et al.

Pageof 11

Search research articles

Showing results (101-110 of 106) with videos related to

Sort By:

Pageof 11

You have reached the last page of results.This site can display upto 106 results.

Molecular Cancer Therapeutics|May 23, 2024

PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast CancerAnran Chen, Beom-Jun Kim, Aparna Mitra, et al.

Cancer Cell|January 15, 2021

MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA DamagePeter Kalev, Marc L Hyer, Stefan Gross, et al.

Biorxiv : the Preprint Server for Biology|December 9, 2024

Reciprocal links between methionine metabolism, DNA repair and therapy resistance in glioblastomaNavyateja Korimerla, Baharan Meghdadi, Isra Haq, et al.

Nature Medicine|January 16, 2018

A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatmentMarc L Hyer, Michael A Milhollen, Jeff Ciavarri, et al.

Nature Communications|June 13, 2026

The PLK4 inhibitor RP-1664 demonstrates potent efficacy in neuroblastoma preclinical models through a dual mechanism of sensitivityIsabel Soria-Bretones, Matias Casás-Selves, Minu Samanta, et al.

Journal of Medicinal Chemistry|November 11, 2011

Discovery of a potent and orally bioavailable benzolactam-derived inhibitor of Polo-like kinase 1 (MLN0905)Matthew O Duffey, Tricia J Vos, Ruth Adams, et al.

Pageof 11